Avadel Pharmaceuticals (AVDL) Operating Income: 2009-2021
Historic Operating Income for Avadel Pharmaceuticals (AVDL) over the last 12 years, with Dec 2021 value amounting to -$23.1 million.
- Avadel Pharmaceuticals' Operating Income fell 62.24% to -$23.1 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$85.5 million, marking a year-over-year decrease of 1571.13%. This contributed to the annual value of -$85.5 million for FY2021, which is 1571.13% down from last year.
- Avadel Pharmaceuticals' Operating Income amounted to -$23.1 million in Q4 2021, which was up 9.85% from -$25.7 million recorded in Q3 2021.
- Avadel Pharmaceuticals' 5-year Operating Income high stood at $40.3 million for Q2 2020, and its period low was -$75.4 million during Q4 2018.
- Its 3-year average for Operating Income is -$8.7 million, with a median of -$10.9 million in 2019.
- Per our database at Business Quant, Avadel Pharmaceuticals' Operating Income slumped by 1,748.55% in 2018 and then spiked by 1,004.72% in 2020.
- Avadel Pharmaceuticals' Operating Income (Quarterly) stood at -$4.1 million in 2017, then crashed by 1,748.55% to -$75.4 million in 2018, then skyrocketed by 90.26% to -$7.3 million in 2019, then slumped by 94.09% to -$14.3 million in 2020, then tumbled by 62.24% to -$23.1 million in 2021.
- Its Operating Income was -$23.1 million in Q4 2021, compared to -$25.7 million in Q3 2021 and -$21.9 million in Q2 2021.